Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 442,209 | 79,148 | 74,081 | 129,126 | 132,139 |
| Marketable Securities | 72,221 | 62,822 | 57,501 | 122,744 | 144,101 |
| Receivables | 392,046 | 305,628 | 265,384 | 231,516 | 190,121 |
| Inventories | 129,029 | 125,586 | 146,953 | 155,202 | 157,759 |
| Other current assets | 51,464 | 57,580 | 55,846 | 25,374 | 20,390 |
| TOTAL | $1,086,969 | $630,764 | $599,765 | $663,962 | $644,510 |
| Non-Current Assets | |||||
| Investments And Advances | 61,538 | 59,136 | 48,757 | 28,590 | 1,907 |
| Other Non-Current Assets | 380,330 | 373,353 | 376,502 | 10,061 | 10,271 |
| TOTAL | $441,868 | $432,489 | $425,259 | $38,651 | $12,178 |
| Total Assets | $1,528,837 | $1,063,253 | $1,025,024 | $702,613 | $656,689 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 148,845 | 107,508 | 112,336 | 134,021 | 133,932 |
| Accrued Expenses | 18,655 | 21,850 | 15,014 | 10,610 | 5,135 |
| Other current liabilities | 596 | 2,124 | 1,993 | 2,256 | 2,947 |
| TOTAL | $187,108 | $153,760 | $156,810 | $171,889 | $160,209 |
| Non-Current Liabilities | |||||
| Long Term Debt | 745,140 | 245,645 | 245,340 | 245,037 | 244,733 |
| Deferred Revenues | 17,190 | 21,234 | 26,399 | 23,911 | 17,079 |
| Other Non-Current Liabilities | 6,595 | 7,021 | 7,308 | 7,588 | 7,860 |
| TOTAL | $758,598 | $261,473 | $260,996 | $254,292 | $259,191 |
| Total Liabilities | $945,706 | $415,233 | $417,806 | $426,181 | $419,400 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 153,084 | 159,688 | 158,760 | 158,666 | 158,755 |
| Common Shares | 160 | 159 | 159 | 159 | 159 |
| Retained earnings | -1,062,238 | -1,082,015 | -1,105,052 | -1,495,947 | -1,524,134 |
| Other shareholders' equity | -226 | -234 | -234 | 8 | -117 |
| TOTAL | $583,131 | $648,020 | $607,218 | $276,432 | $237,289 |
| Total Liabilities And Equity | $1,528,837 | $1,063,253 | $1,025,024 | $702,613 | $656,689 |